CDT Stock Summary and Trading Ideas (CDT Equity | NASDAQ:CDT)

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

CDT Equity trades on the NASDAQ stock market under the symbol CDT.

As of December 29, 2025, CDT stock price declined to $1.42 with 57,199 million shares trading.

CDT has a beta of 2.05, meaning it tends to be more sensitive to market movements. CDT has a correlation of 0.04 to the broad based SPY ETF.

CDT has a market cap of $2.31 million. This is considered a Sub-Micro Cap stock.

CDT has underperformed the market in the last year with a price return of -99.8% while the SPY ETF gained +15.6%. CDT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -74.4% and -18.9%, respectively, while the SPY returned +4.2% and +1.2%, respectively.

CDT support price is $1.31 and resistance is $1.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDT shares will trade within this expected range on the day.